Claims for Patent: 10,406,213

Summary for Patent: 10,406,213

Title:	Injection paradigm for administration of botulinum toxins
Abstract:	Methods for treating a patient suffering from a medication overuse headache disorder are provided. The methods comprise administering to a patient suffering from a medication overuse disorder a Clostridial toxin. The toxin is administered to the frontalis, corrugator, procerus, occipitalis, temporalis, trapezius and cervical paraspinal muscles of the patient.
Inventor(s):	Turkel; Catherine C. (Newport Coast, CA), Aurora; Sheena K. (Seattle, WA), Brin; Mitchell F. (Newport Beach, CA)
Assignee:	Allergan, Inc. (Irvine, CA)
Application Number:	15/707,452
Patent Claims:	1. A method for treating or reducing the occurrence of a symptom of a medication overuse headache disorder in a patient in need thereof, the method comprising: local administration of a botulinum neurotoxin to the frontalis, corrugator, procereus procerus, occipitalis, temporalis, trapezius and cervical paraspinal muscles of the patient that suffers from the migraine headache; wherein the botulinum neurotoxin is administered, to the frontalis at about twenty units divided among four sites of injection; to the corrugator at about ten units divided among two sites of injection; to the procerus at about five units to one site of injection; to the occipitalis at about thirty units divided among six sites of injection to about forty units divided among eight sites of injection; to the temporalis at about forty units divided among eight sites of injection up to fifty units divided among ten sites of injection; to the trapezius at about thirty units divided among six sites of injection up to about fifty units divided among ten sites of injection and to the cervical paraspinal muscles at about twenty units divided among four sites of injection; wherein the botulinum neurotoxin is injected at 31 to 39 injection sites; to thereby treat or reduce the occurrence of a symptom of a medication overuse headache disorder in the patient. 2. The method of claim 1, wherein the medication overuse headache disorder is selected from triptan, opioid overuse disorder and combinations thereof. 3. The method of claim 1, wherein the medication overuse headache disorder is a triptan overuse disorder. 4. The method of claim 1, wherein the medication overuse headache disorder is an opioid overuse disorder. 5. The method of claim 1, wherein the botulinum toxin is type A. 6. The method of claim 5, wherein the total amount of botulinum neurotoxin administered is from about 155 units to about 195 units of onabotulinumtoxinA. 7. The method of claim 1, wherein the botulinum neurotoxin is type B. 8. The method of claim 1, wherein the botulinum neurotoxin is type E. 9. The method of claim 5, wherein the botulinum toxin type A is selected from onabotulinumtoxinA, incobotulinumtoxinA and abobotulinumtoxinA. 10. The method of claim 1, wherein the administration is by injection. 11. The method of claim 1, wherein the administration is by subcutaneous injection. 12. The method of claim 1, wherein the administration is by intramuscular injection.

Details for Patent 10,406,213

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Abbvie Inc.	BOTOX COSMETIC	onabotulinumtoxina	For Injection	103000	December 09, 1991		2030-03-30
Abbvie Inc.	BOTOX	onabotulinumtoxina	For Injection	103000	December 09, 1991		2030-03-30
Ipsen Biopharm Limited	DYSPORT	abobotulinumtoxina	For Injection	125274	April 29, 2009		2030-03-30
Merz Pharmaceuticals Gmbh C/o Merz Pharmaceuticals Llc	XEOMIN	incobotulinumtoxina	For Injection	125360	July 30, 2010		2030-03-30
Merz Pharmaceuticals Gmbh C/o Merz Pharmaceuticals Llc	XEOMIN	incobotulinumtoxina	For Injection	125360	November 20, 2015		2030-03-30